A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies

Bahram Forouzesh, Chris H. Takimoto, Andrew Goetz, Sami Diab, Lisa A. Hammond, Leslie Smetzer, Garry Schwartz, Robert Gazak, John Callaghan, Daniel D. Von Hoff, Eric K. Rowinsky

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: This study was conducted to assess the feasibility of administering the oral diarylsulfonylurea (DSU) ILX-295501 on a weekly for 3 weeks every 4-week schedule. The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity. Experimental Design: The initial starting dose of ILX-295501 was 100 mg/m 2, which was equivalent to one-sixth of the highest dose that did not induce irreversible toxicity in dogs, and, using a modified Fibonnaci search scheme to guide dose level selection, the following dose levels were evaluated: 100, 200, 400, 600, 900, 1350, and 1800 mg/m2. Because severe toxicities were being reported in other trials at doses that encompassed this range and a cumulative toxicity profile was emerging, the study was suspended and then reinitiated to further reevaluate the lower dosing range. In the second part of the study, the following dose levels were selected a priori for evaluation: 400, 800, 1000, 1250, and 1500 mg/m2; and a modified continual reassessment model was used for dose assignment to determine the MTD, which was defined a priori as the highest dose in which the incidence of dose-limiting toxicity in the first course did not exceed 20%. Results: Forty-nine patients were treated with 142 courses of ILX-295501 at doses ranging from 100 to 1800 mg/m2. The incidences of dose-limiting toxicity, principally neutropenia and thrombocytopenia, were unacceptably high at ILX-295501 doses exceeding 1000 mg/m2, which was determined to be the MTD for both minimally pretreated and heavily pretreated (HP) patients. In contrast to the first generation of DSUs, particularly sulofenur, clinically relevant levels of oxidized hemoglobin (methemoglobin) and secondary hemolytic anemia, were not noted. One HP patient with non-small cell lung carcinoma experienced a partial response. Pharmacokinetic studies revealed that ILX-295501 was absorbed slowly, with peak plasma concentrations (C max) achieving 6.02 h, on average, after oral administration. The pharmacokinetic behavior of ILX-295501 was characterized by dose proportionality, a relatively small apparent volume of distribution at steady state (Vss/F), averaging 8.02 ± 14.08 liters, and low apparent total body clearance (CLt/F) rate (mean, 0.036 ± 0.116 liters/h). The initial drug distribution phase was rapid [harmonic mean half-life (t1/2α), 2.1 ± 7.0 min], whereas the terminal elimination phase was slow (harmonic mean t1/2β, 150.6 ± 80.2 h). Conclusions: The recommended dose for Phase II studies of the oral DSU ILX-295501 administered weekly for 3 weeks every 4 weeks is 1000 mg/m 2/day for both minimally pretreated and HP patients. The characteristics of the myelosuppressive effects of ILX-295501, the paucity of severe nonhematological toxicities, and preliminary antitumor activity warrant disease-directed evaluations of ILX-295501.

Original languageEnglish (US)
Pages (from-to)5540-5549
Number of pages10
JournalClinical Cancer Research
Volume9
Issue number15
StatePublished - Nov 15 2003

Fingerprint

N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea
Appointments and Schedules
Pharmacokinetics
Neoplasms
Maximum Tolerated Dose
sulofenur
Methemoglobin
Hemolytic Anemia
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Forouzesh, B., Takimoto, C. H., Goetz, A., Diab, S., Hammond, L. A., Smetzer, L., ... Rowinsky, E. K. (2003). A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 9(15), 5540-5549.

A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies. / Forouzesh, Bahram; Takimoto, Chris H.; Goetz, Andrew; Diab, Sami; Hammond, Lisa A.; Smetzer, Leslie; Schwartz, Garry; Gazak, Robert; Callaghan, John; Von Hoff, Daniel D.; Rowinsky, Eric K.

In: Clinical Cancer Research, Vol. 9, No. 15, 15.11.2003, p. 5540-5549.

Research output: Contribution to journalArticle

Forouzesh, B, Takimoto, CH, Goetz, A, Diab, S, Hammond, LA, Smetzer, L, Schwartz, G, Gazak, R, Callaghan, J, Von Hoff, DD & Rowinsky, EK 2003, 'A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies', Clinical Cancer Research, vol. 9, no. 15, pp. 5540-5549.
Forouzesh, Bahram ; Takimoto, Chris H. ; Goetz, Andrew ; Diab, Sami ; Hammond, Lisa A. ; Smetzer, Leslie ; Schwartz, Garry ; Gazak, Robert ; Callaghan, John ; Von Hoff, Daniel D. ; Rowinsky, Eric K. / A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 15. pp. 5540-5549.
@article{da6bddc7116a4435a67bb6419b98e6f9,
title = "A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies",
abstract = "Purpose: This study was conducted to assess the feasibility of administering the oral diarylsulfonylurea (DSU) ILX-295501 on a weekly for 3 weeks every 4-week schedule. The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity. Experimental Design: The initial starting dose of ILX-295501 was 100 mg/m 2, which was equivalent to one-sixth of the highest dose that did not induce irreversible toxicity in dogs, and, using a modified Fibonnaci search scheme to guide dose level selection, the following dose levels were evaluated: 100, 200, 400, 600, 900, 1350, and 1800 mg/m2. Because severe toxicities were being reported in other trials at doses that encompassed this range and a cumulative toxicity profile was emerging, the study was suspended and then reinitiated to further reevaluate the lower dosing range. In the second part of the study, the following dose levels were selected a priori for evaluation: 400, 800, 1000, 1250, and 1500 mg/m2; and a modified continual reassessment model was used for dose assignment to determine the MTD, which was defined a priori as the highest dose in which the incidence of dose-limiting toxicity in the first course did not exceed 20{\%}. Results: Forty-nine patients were treated with 142 courses of ILX-295501 at doses ranging from 100 to 1800 mg/m2. The incidences of dose-limiting toxicity, principally neutropenia and thrombocytopenia, were unacceptably high at ILX-295501 doses exceeding 1000 mg/m2, which was determined to be the MTD for both minimally pretreated and heavily pretreated (HP) patients. In contrast to the first generation of DSUs, particularly sulofenur, clinically relevant levels of oxidized hemoglobin (methemoglobin) and secondary hemolytic anemia, were not noted. One HP patient with non-small cell lung carcinoma experienced a partial response. Pharmacokinetic studies revealed that ILX-295501 was absorbed slowly, with peak plasma concentrations (C max) achieving 6.02 h, on average, after oral administration. The pharmacokinetic behavior of ILX-295501 was characterized by dose proportionality, a relatively small apparent volume of distribution at steady state (Vss/F), averaging 8.02 ± 14.08 liters, and low apparent total body clearance (CLt/F) rate (mean, 0.036 ± 0.116 liters/h). The initial drug distribution phase was rapid [harmonic mean half-life (t1/2α), 2.1 ± 7.0 min], whereas the terminal elimination phase was slow (harmonic mean t1/2β, 150.6 ± 80.2 h). Conclusions: The recommended dose for Phase II studies of the oral DSU ILX-295501 administered weekly for 3 weeks every 4 weeks is 1000 mg/m 2/day for both minimally pretreated and HP patients. The characteristics of the myelosuppressive effects of ILX-295501, the paucity of severe nonhematological toxicities, and preliminary antitumor activity warrant disease-directed evaluations of ILX-295501.",
author = "Bahram Forouzesh and Takimoto, {Chris H.} and Andrew Goetz and Sami Diab and Hammond, {Lisa A.} and Leslie Smetzer and Garry Schwartz and Robert Gazak and John Callaghan and {Von Hoff}, {Daniel D.} and Rowinsky, {Eric K.}",
year = "2003",
month = "11",
day = "15",
language = "English (US)",
volume = "9",
pages = "5540--5549",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies

AU - Forouzesh, Bahram

AU - Takimoto, Chris H.

AU - Goetz, Andrew

AU - Diab, Sami

AU - Hammond, Lisa A.

AU - Smetzer, Leslie

AU - Schwartz, Garry

AU - Gazak, Robert

AU - Callaghan, John

AU - Von Hoff, Daniel D.

AU - Rowinsky, Eric K.

PY - 2003/11/15

Y1 - 2003/11/15

N2 - Purpose: This study was conducted to assess the feasibility of administering the oral diarylsulfonylurea (DSU) ILX-295501 on a weekly for 3 weeks every 4-week schedule. The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity. Experimental Design: The initial starting dose of ILX-295501 was 100 mg/m 2, which was equivalent to one-sixth of the highest dose that did not induce irreversible toxicity in dogs, and, using a modified Fibonnaci search scheme to guide dose level selection, the following dose levels were evaluated: 100, 200, 400, 600, 900, 1350, and 1800 mg/m2. Because severe toxicities were being reported in other trials at doses that encompassed this range and a cumulative toxicity profile was emerging, the study was suspended and then reinitiated to further reevaluate the lower dosing range. In the second part of the study, the following dose levels were selected a priori for evaluation: 400, 800, 1000, 1250, and 1500 mg/m2; and a modified continual reassessment model was used for dose assignment to determine the MTD, which was defined a priori as the highest dose in which the incidence of dose-limiting toxicity in the first course did not exceed 20%. Results: Forty-nine patients were treated with 142 courses of ILX-295501 at doses ranging from 100 to 1800 mg/m2. The incidences of dose-limiting toxicity, principally neutropenia and thrombocytopenia, were unacceptably high at ILX-295501 doses exceeding 1000 mg/m2, which was determined to be the MTD for both minimally pretreated and heavily pretreated (HP) patients. In contrast to the first generation of DSUs, particularly sulofenur, clinically relevant levels of oxidized hemoglobin (methemoglobin) and secondary hemolytic anemia, were not noted. One HP patient with non-small cell lung carcinoma experienced a partial response. Pharmacokinetic studies revealed that ILX-295501 was absorbed slowly, with peak plasma concentrations (C max) achieving 6.02 h, on average, after oral administration. The pharmacokinetic behavior of ILX-295501 was characterized by dose proportionality, a relatively small apparent volume of distribution at steady state (Vss/F), averaging 8.02 ± 14.08 liters, and low apparent total body clearance (CLt/F) rate (mean, 0.036 ± 0.116 liters/h). The initial drug distribution phase was rapid [harmonic mean half-life (t1/2α), 2.1 ± 7.0 min], whereas the terminal elimination phase was slow (harmonic mean t1/2β, 150.6 ± 80.2 h). Conclusions: The recommended dose for Phase II studies of the oral DSU ILX-295501 administered weekly for 3 weeks every 4 weeks is 1000 mg/m 2/day for both minimally pretreated and HP patients. The characteristics of the myelosuppressive effects of ILX-295501, the paucity of severe nonhematological toxicities, and preliminary antitumor activity warrant disease-directed evaluations of ILX-295501.

AB - Purpose: This study was conducted to assess the feasibility of administering the oral diarylsulfonylurea (DSU) ILX-295501 on a weekly for 3 weeks every 4-week schedule. The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity. Experimental Design: The initial starting dose of ILX-295501 was 100 mg/m 2, which was equivalent to one-sixth of the highest dose that did not induce irreversible toxicity in dogs, and, using a modified Fibonnaci search scheme to guide dose level selection, the following dose levels were evaluated: 100, 200, 400, 600, 900, 1350, and 1800 mg/m2. Because severe toxicities were being reported in other trials at doses that encompassed this range and a cumulative toxicity profile was emerging, the study was suspended and then reinitiated to further reevaluate the lower dosing range. In the second part of the study, the following dose levels were selected a priori for evaluation: 400, 800, 1000, 1250, and 1500 mg/m2; and a modified continual reassessment model was used for dose assignment to determine the MTD, which was defined a priori as the highest dose in which the incidence of dose-limiting toxicity in the first course did not exceed 20%. Results: Forty-nine patients were treated with 142 courses of ILX-295501 at doses ranging from 100 to 1800 mg/m2. The incidences of dose-limiting toxicity, principally neutropenia and thrombocytopenia, were unacceptably high at ILX-295501 doses exceeding 1000 mg/m2, which was determined to be the MTD for both minimally pretreated and heavily pretreated (HP) patients. In contrast to the first generation of DSUs, particularly sulofenur, clinically relevant levels of oxidized hemoglobin (methemoglobin) and secondary hemolytic anemia, were not noted. One HP patient with non-small cell lung carcinoma experienced a partial response. Pharmacokinetic studies revealed that ILX-295501 was absorbed slowly, with peak plasma concentrations (C max) achieving 6.02 h, on average, after oral administration. The pharmacokinetic behavior of ILX-295501 was characterized by dose proportionality, a relatively small apparent volume of distribution at steady state (Vss/F), averaging 8.02 ± 14.08 liters, and low apparent total body clearance (CLt/F) rate (mean, 0.036 ± 0.116 liters/h). The initial drug distribution phase was rapid [harmonic mean half-life (t1/2α), 2.1 ± 7.0 min], whereas the terminal elimination phase was slow (harmonic mean t1/2β, 150.6 ± 80.2 h). Conclusions: The recommended dose for Phase II studies of the oral DSU ILX-295501 administered weekly for 3 weeks every 4 weeks is 1000 mg/m 2/day for both minimally pretreated and HP patients. The characteristics of the myelosuppressive effects of ILX-295501, the paucity of severe nonhematological toxicities, and preliminary antitumor activity warrant disease-directed evaluations of ILX-295501.

UR - http://www.scopus.com/inward/record.url?scp=0344629833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344629833&partnerID=8YFLogxK

M3 - Article

C2 - 14654534

AN - SCOPUS:0344629833

VL - 9

SP - 5540

EP - 5549

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -